ArticleJournal of experimental & clinical cancer research : CR2026
CXCL9-driven immune rewiring and tumor-intrinsic ATR signaling inhibition restore radiotherapy response in lung cancer.
Article in Journal of experimental & clinical cancer research : CR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundNon-small cell lung cancer (NSCLC) accounts for ~ 85% of lung cancers and is associated with poor outcomes in advanced stages. Radiotherapy (RT) is central to NSCLC treatment, yet locoregional relapse remains frequent. Increasing evidence indicates that, beyond tumor-intrinsic adaptations, the tumor microenvironment (TME) and immune contexture critically influence response to irradiation. However, most radioresistance models rely on human cell lines unsuitable for immunocompetent systems, limiting insight into immune-tumor interactions.
methodsWe generated radioresistant (RR) isogenic variants of murine lung adenocarcinoma cell lines and investigated RT resistance using transcriptomics, 3D co-culture systems, and syngeneic mouse models.
resultsRR clones showed stable adaptations to DNA damage, including enhanced clonogenic survival, reduced immunogenic cell death, and constitutive activation of DNA damage response pathways, particularly ATR signaling. High ATR levels in NSCLC patients were significantly associated with immunosuppression. Transcriptomics revealed altered DNA repair and downregulation of type-I interferon and innate immune pathways. In vivo, RR tumors exhibited an immunosuppressive TME with increased T regulatory cells, M2-like macrophages, and myeloid-derived suppressor cells, alongside reduced cytotoxic T cell recruitment. In 3D co-cultures, immunosuppressive cells protected cancer cells from RT-induced cytotoxicity. Notably, RR tumors regained RT sensitivity in immunodeficient mice, highlighting the role of immune suppression in radioresistance. Therapeutically, activation of innate immunity using TLR3-TLR7/8 agonists (poly(I:C)+R848) restored antitumor responses and improved RT efficacy, partly via CXCL9/10-mediated immune recruitment. ATR inhibition with ceralasertib further sensitized RR tumors to RT.
conclusionThese findings identify cancer cell-intrinsic ATR signaling and immune suppression as key drivers of radioresistance and support combined therapeutic strategies to prevent locoregional relapse in NSCLC after radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.